Novel Risk Factors for Recurrent Clostridium Difficile Infection in Children

Overview

Journal J Pediatr Gastroenterol Nutr

Publisher Wiley

Date 2014 Sep 9

PMID 25199038

Citations 35

Authors

Maribeth R Nicholson

Isaac P Thomsen

James C Slaughter

C Buddy Creech

Kathryn M Edwards

Affiliations

Soon will be listed here.

Abstract

Objectives: Clostridium difficile, a common cause of antibiotic-associated diarrhea, has been reported to recur in high rates in adults. The rates and risk factors for recurrent C difficile infection (rCDI) in children have not been well established.

Methods: We conducted a retrospective cohort study of 186 pediatric patients seen at a tertiary care referral center for a 5-year period diagnosed as having a primary C difficile infection. Children with recurrent disease, defined as return of symptoms of C difficile infection and positive testing ≤60 days after the completion of therapy, were compared with children who did not experience an episode of recurrence.

Results: Of the 186 pediatric patients included in this study, 41 (22%) experienced rCDI. On univariable analysis, factors significantly associated with rCDI included malignancy, recent hospitalization, recent surgery, antibiotic use, number of antibiotic exposures by class, acid blocker use, immunosuppressant use, and hospital-acquired disease. On multivariable analysis, malignancy (odds ratio [OR] 3.39, 95% confidence interval [CI] 1.52-7.85), recent surgery (OR 2.40, 95% CI 1.05-5.52), and the number of antibiotic exposures by class (OR 1.33, 95% CI 1.01-1.75) were significantly associated with recurrent disease in children.

Conclusions: The rate of rCDI in children was 22%. Recurrence was significantly associated with the risk factors of malignancy, recent surgery, and the number of antibiotic exposures by class.

Citing Articles

infection: history, epidemiology, risk factors, prevention, clinical manifestations, treatment, and future options.

Di Bella S, Sanson G, Monticelli J, Zerbato V, Principe L, Giuffre M Clin Microbiol Rev. 2024; 37(2):e0013523.

PMID: 38421181 PMC: 11324037. DOI: 10.1128/cmr.00135-23.

Antimicrobial Resistance of in Children from a Tertiary Pediatric Hospital in Shanghai, China.

Li X, Wang Y, Cao R, Xiao F, Wang X, Ye L Infect Drug Resist. 2024; 17:329-339.

PMID: 38293314 PMC: 10826549. DOI: 10.2147/IDR.S441312.

Infections among Pediatric Patients Hospitalized at an Oncology Department of a Tertiary Hospital in Poland.

Lemiech-Mirowska E, Gaszynska E, Sierocka A, Kiersnowska Z, Marczak M Medicina (Kaunas). 2023; 59(8).

PMID: 37629653 PMC: 10456884. DOI: 10.3390/medicina59081363.

Double-Blind, Placebo-Controlled Study of Bezlotoxumab in Children Receiving Antibacterial Treatment for Clostridioides difficile Infection (MODIFY III).

Sferra T, Merta T, Neely M, de Oliveira C, Lassaletta A, Fortuny Guasch C J Pediatric Infect Dis Soc. 2023; 12(6):334-341.

PMID: 37389891 PMC: 10312293. DOI: 10.1093/jpids/piad031.

Fecal Microbiota Transplantation for Clostridioides difficile Infection in Immunocompromised Pediatric Patients.

Conover K, Absah I, Ballal S, Brumbaugh D, Cho S, Cardenas M J Pediatr Gastroenterol Nutr. 2023; 76(4):440-446.

PMID: 36720105 PMC: 10627107. DOI: 10.1097/MPG.0000000000003714.

References

Khanna S, Baddour L, Huskins W, Kammer P, Faubion W, Zinsmeister A . The epidemiology of Clostridium difficile infection in children: a population-based study. Clin Infect Dis. 2013; 56(10):1401-6. PMC: 3693491. DOI: 10.1093/cid/cit075. View

Jangi S, Lamont J . Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life. J Pediatr Gastroenterol Nutr. 2010; 51(1):2-7. DOI: 10.1097/MPG.0b013e3181d29767. View

Linsky A, Gupta K, Lawler E, Fonda J, Hermos J . Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med. 2010; 170(9):772-8. DOI: 10.1001/archinternmed.2010.73. View

Babrowski T, Holbrook C, Moss J, Gottlieb L, Valuckaite V, Zaborin A . Pseudomonas aeruginosa virulence expression is directly activated by morphine and is capable of causing lethal gut-derived sepsis in mice during chronic morphine administration. Ann Surg. 2011; 255(2):386-93. PMC: 3258463. DOI: 10.1097/SLA.0b013e3182331870. View

Hojsak I, Ferenc T, Bojanic K, Misak Z, Mocic Pavic A, Lukic-Grlic A . Incidence of Clostridium difficile infection in children with inflammatory bowel disease compared to oncology and immunocompetent patients. Digestion. 2012; 86(1):6-11. DOI: 10.1159/000337357. View

Tschudin-Sutter S, Tamma P, Milstone A, Perl T . Predictors of first recurrence of Clostridium difficile infections in children. Pediatr Infect Dis J. 2013; 33(4):414-6. DOI: 10.1097/INF.0000000000000108. View

Lubbert C, Johann C, Kekule A, Worlitzsch D, Weis S, Mossner J . [Immunosuppressive treatment as a risk factor for the occurrence of clostridium difficile infection (CDI)]. Z Gastroenterol. 2013; 51(11):1251-8. DOI: 10.1055/s-0033-1335505. View

Zilberberg M, Reske K, Olsen M, Yan Y, Dubberke E . Risk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort study. BMC Infect Dis. 2014; 14:306. PMC: 4050409. DOI: 10.1186/1471-2334-14-306. View

McFarland L, Surawicz C, Rubin M, FEKETY R, Elmer G, Greenberg R . Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol. 1999; 20(1):43-50. DOI: 10.1086/501553. View

10.

Eyre D, Walker A, Wyllie D, Dingle K, Griffiths D, Finney J . Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis. 2012; 55 Suppl 2:S77-87. PMC: 3388024. DOI: 10.1093/cid/cis356. View

11.

McFarland L, Elmer G, Surawicz C . Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002; 97(7):1769-75. DOI: 10.1111/j.1572-0241.2002.05839.x. View

12.

Cohen S, Gerding D, Johnson S, Kelly C, Loo V, McDonald L . Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010; 31(5):431-55. DOI: 10.1086/651706. View

13.

Kim J, Smathers S, Prasad P, Leckerman K, Coffin S, Zaoutis T . Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006. Pediatrics. 2008; 122(6):1266-70. DOI: 10.1542/peds.2008-0469. View

14.

Zerey M, Paton B, Lincourt A, Gersin K, Kercher K, Heniford B . The burden of Clostridium difficile in surgical patients in the United States. Surg Infect (Larchmt). 2008; 8(6):557-66. DOI: 10.1089/sur.2006.062. View

15.

Maroo S, Lamont J . Recurrent clostridium difficile. Gastroenterology. 2006; 130(4):1311-6. DOI: 10.1053/j.gastro.2006.02.044. View

16.

Marsh J, Arora R, Schlackman J, Shutt K, Curry S, Harrison L . Association of relapse of Clostridium difficile disease with BI/NAP1/027. J Clin Microbiol. 2012; 50(12):4078-82. PMC: 3502988. DOI: 10.1128/JCM.02291-12. View

17.

Elliott B, Chang B, Golledge C, Riley T . Clostridium difficile-associated diarrhoea. Intern Med J. 2007; 37(8):561-8. DOI: 10.1111/j.1445-5994.2007.01403.x. View

18.

Kyne L, Kelly C . Recurrent Clostridium difficile diarrhoea. Gut. 2001; 49(1):152-3. PMC: 1728368. DOI: 10.1136/gut.49.1.152. View

19.

Garey K, Sethi S, Yadav Y, DuPont H . Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect. 2008; 70(4):298-304. DOI: 10.1016/j.jhin.2008.08.012. View

20.

McFarland L, Surawicz C, Greenberg R, FEKETY R, Elmer G, Moyer K . A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994; 271(24):1913-8. View